A Phase II Multi-center Open-label Study Evaluating GRN1005 Alone or in Combination with Trastuzumab in Breast Cancer Patients with Brain Metastases
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The main purpose of this research study is to see if an investigational drug, GRN1005 can shrink tumor cells that have spread to the brain.
Description
The main purpose of this research study is to see if an investigational drug, GRN1005 can shrink tumor cells that have spread to the brain.
Details
| Condition | Breast Cancer,Brain Cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX2236 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.